A higher frequency of neuromuscular junction dysfunction in patients treated with anti-PD-1/PD-L1 compared to those treated with anti-CTLA-4 was also observed in a large cohort of patients (14); in the same cohort, Guillain-Barré syndrome and non-infectious meningitis were more frequent in the group of patients treated with combined anti-PD-L1 and CTLA-4 therapy compared to monotherapy. This evidence concerns the gene CTLA4 and Guillain-Barre syndrome.